STOCK TITAN

Atea Pharmaceuticals (AVIR) Stock News, Sep 2022-Feb 2023

AVIR NASDAQ

Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.

Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.

Rhea-AI Summary

BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that its CEO, Jean-Pierre Sommadossi, will present a business update during a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:00 p.m. ET. A live webcast of the event will be accessible here and will remain available for 90 days after the event.

Atea specializes in developing oral therapies for severe viral diseases, focusing on antiviral treatments for COVID-19, dengue, and HCV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) provided a clinical update, highlighting progress in its pipeline for 2023. The SUNRISE-3 Phase 3 trial for bemnifosbuvir, targeting high-risk, non-hospitalized COVID-19 patients, continues with interim analysis expected in 2H23. The company anticipates proof-of-concept results for AT-752 for dengue in 1Q23, and initiation of a Phase 2 study of bemnifosbuvir and ruzasvir for Hepatitis C in 2Q23, with data expected in 4Q23. Atea boasts a strong balance sheet to support these initiatives through 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:00 p.m. PT in San Francisco. A live webcast of the presentation will be available on Atea's website and will remain accessible for 90 days. Atea, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for severe viral diseases, including COVID-19, dengue, and hepatitis C.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
Rhea-AI Summary

Atea Pharmaceuticals (AVIR) has initiated the SUNRISE-3 Phase 3 trial to evaluate bemnifosbuvir, an oral antiviral treatment for COVID-19, in high-risk non-hospitalized patients. The trial aims to enroll at least 1,500 participants and will assess its efficacy against hospitalization and death. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase, boasting a unique mechanism that helps mitigate resistance. Previous late-stage trials indicated a 71% reduction in hospitalization rates for treated patients compared to placebo. This development highlights Atea's focus on unmet medical needs in COVID-19 treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will present a business update at the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 9:40 a.m. ET. A live webcast will be available on the company’s website, with an archived version accessible for 90 days post-event.

Atea focuses on developing oral antiviral therapies for severe diseases, including COVID-19, hepatitis C, and dengue, leveraging its nucleos(t)ide prodrug platform to address unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.20%
Tags
conferences
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the Jefferies London Healthcare Conference on November 15, 2022, at 5:00 p.m. GMT / 12:00 p.m. ET. The event will be accessible via a live webcast and archived for 90 days post-event. Atea focuses on developing oral therapies for severe viral infections, leveraging its nucleos(t)ide prodrug platform. Current efforts include targeting COVID-19, hepatitis C, and other severe viral diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.40%
Tags
conferences
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced key updates and financial results for Q3 2022, reporting a net loss of $8.1 million, down from a loss of $28.2 million in 2021. The company holds $665 million in cash and marketable securities. Notably, the SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients is set to enroll before year-end 2022. Additionally, Atea plans to submit trial applications for a hepatitis C combination study. Research and development expenses decreased significantly, attributed to the termination of a cost-sharing agreement with Roche.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.88%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals (AVIR) provided updates on AT-752, an oral antiviral for dengue fever, during the ASTMH 2022 Annual Meeting. The Phase 1 trial showed that AT-752 was well tolerated at doses up to 1500 mg, achieving plasma levels above the in vitro EC90. The FDA has given Fast Track designation for AT-752, making it a promising option for treating dengue, which affects 400 million annually. Atea is advancing two proof-of-concept studies to evaluate AT-752's safety and efficacy against dengue, aiming to fill the existing treatment gap.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 7, 2022, at 4:30 p.m. ET, to report financial results for Q3 2022 and provide a business update. The call can be accessed via registration, with a webcast available in the Investor Relations section of the company's website. Atea focuses on developing oral therapies for severe diseases, particularly targeting ssRNA viruses, including SARS-CoV-2, HCV, dengue, and RSV. The company aims to expand its antiviral pipeline through its proprietary nucleos(t)ide prodrug platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences earnings date
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced that the FDA granted Fast Track Designation to AT-752, an oral antiviral for dengue treatment. This designation aims to expedite development, acknowledging the urgent need for effective treatments as there are currently no approved options. AT-752 has shown promising preclinical activity against dengue and safety in Phase 1 trials. The company is advancing two Phase 2 studies to assess AT-752’s efficacy and safety in adults with dengue virus infections, with initial data expected soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags

FAQ

What is the current stock price of Atea Pharmaceuticals (AVIR)?

Atea Pharmaceuticals (AVIR) last closed at $3.96.

What is the market cap of Atea Pharmaceuticals (AVIR)?

The market cap of Atea Pharmaceuticals (AVIR) is approximately $318.0M.